KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity.
- Poirel L Emerging Antibiotic Resistance Unit and Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland laurent.poirel@unifr.ch.
- Vuillemin X Emerging Antibiotic Resistance Unit and Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
- Juhas M Emerging Antibiotic Resistance Unit and Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
- Masseron A Emerging Antibiotic Resistance Unit and Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
- Bechtel-Grosch U Department of Trauma Surgery, University Hospital of Zürich, Zürich, Switzerland.
- Tiziani S Institute of Intensive Medicine, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
- Mancini S Institute of Medical Microbiology, University of Zürich, Zürich, Switzerland.
- Nordmann P Emerging Antibiotic Resistance Unit and Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
- 2020-05-28
Published in:
- Antimicrobial agents and chemotherapy. - 2020
English
KPC-50 is a KPC-3 variant identified from a Klebsiella pneumoniae clinical isolate recovered in Switzerland in 2019. Compared to KPC-3, KPC-50 shows (i) a three-amino-acid insertion (Glu-Ala-Val) between amino acids 276 and 277, (ii) an increased affinity to ceftazidime, (iii) a decreased sensitivity to avibactam, explaining the ceftazidime-avibactam resistance, and (iv) an association with a sharp reduction of its carbapenemase activity.
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.1128/AAC.00321-20
- PMID 32457107
- Persistent URL
- https://sonar.ch/global/documents/26818
Statistics
Document views: 28
File downloads:
- Full-text: 0